Noscendo
Noscendo is a leading provider of software-based pathogen identification, aiming to revolutionize infection diagnostics and save lives by combining molecular biological methods like Next-Generation Sequencing with proprietary Bio-IT solutions within their DISQVER® platform. Their innovative platform enables rapid and precise detection of a wide range of microbes from blood samples, supporting clinical decision-making in infectious diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Providing and obtaining one or more data sets via a digital communication network
US-12339983-B2
View DetailsMethods and devices for nucleic acid-based real-time determination of disease states
US-11749378-B2
View Details
Providing and obtaining one or more data sets via a digital communication network
US-12339983-B2
View DetailsMethods and devices for nucleic acid-based real-time determination of disease states
US-11749378-B2
View DetailsProducts
Digital pathogen diagnostics platform (NGS + bioinformatics)
An integrated diagnostic platform that combines next-generation sequencing of cell-free DNA with bioinformatics matching to a clinical genome database to identify microbial species in patient blood samples.
Digital pathogen diagnostics platform (NGS + bioinformatics)
An integrated diagnostic platform that combines next-generation sequencing of cell-free DNA with bioinformatics matching to a clinical genome database to identify microbial species in patient blood samples.
Services
Laboratory service that sequences cell-free DNA from patient blood samples and uses bioinformatics comparison to a clinical genomic database to identify pathogens and provide a diagnostic report.
Laboratory service that sequences cell-free DNA from patient blood samples and uses bioinformatics comparison to a clinical genomic database to identify pathogens and provide a diagnostic report.
Expertise Areas
- Digital pathogen diagnostics
- Next-generation sequencing (NGS) for clinical diagnostics
- Cell-free DNA analysis
- Bioinformatics for microbial identification
Key Technologies
- Next-generation sequencing (NGS)
- Cell-free DNA analysis
- Bioinformatics / pathogen identification algorithms
- Clinical pathogen genome reference database
News & Updates
Numerous lectures at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) congress in April 2025 in Vienna will showcase the broad application possibilities of Next-Generation Sequencing (NGS) platforms like DISQVER® for infection diagnostics, capable of identifying over 16,000 microbes in a single sample.
The World Health Organization's recent report highlights DISQVER® as the only commercially available NGS platform approved for clinical use in diagnosing invasive fungal diseases (IFDs), emphasizing its significance in infectious disease diagnostics.
The DigiSep study, which investigates the benefits of digital pathogen diagnostics like DISQVER® for sepsis and septic shock patients, has been completed and its promising results have been submitted to the German Federal Joint Committee (G-BA) for further evaluation.
Numerous lectures at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) congress in April 2025 in Vienna will showcase the broad application possibilities of Next-Generation Sequencing (NGS) platforms like DISQVER® for infection diagnostics, capable of identifying over 16,000 microbes in a single sample.
The World Health Organization's recent report highlights DISQVER® as the only commercially available NGS platform approved for clinical use in diagnosing invasive fungal diseases (IFDs), emphasizing its significance in infectious disease diagnostics.
The DigiSep study, which investigates the benefits of digital pathogen diagnostics like DISQVER® for sepsis and septic shock patients, has been completed and its promising results have been submitted to the German Federal Joint Committee (G-BA) for further evaluation.